#381 ‒ Alzheimer’s disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D. | The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

This podcast explores the disproportionate impact of Alzheimer's disease on women, challenging the assumption that increased lifespan fully explains the disparity. Neuroscientist Lisa Mosconi discusses how Alzheimer's, for women, is a midlife disease with preclinical changes starting long before symptoms appear. Advanced imaging reveals these early changes, highlighting the role of menopause as a critical brain event affecting energy, structure, and immune signaling. The conversation covers genetic risks like ApoE4, nuanced evidence around menopausal hormonal therapy, and the confusion caused by the WHI. Mosconi introduces the CARE Initiative, aiming to halve women's Alzheimer's risk by 2050 through evidence-based strategies addressing lifestyle, sleep, metabolism, and mood, also involving medications like GLP-1 agonists and CIRMs.

Outlines

Part 1: Introduction, Personal Context

Part 2: Defining Alzheimer's and the Gender Gap

Part 3: Brain Imaging and Estrogen Receptors

Part 4: The CARE Initiative and Genetic Risk

Part 5: Hormone Therapy and Clinical Research

Part 6: Biomarkers and Future Outlook

Sign in to continue reading, translating and more.

Continue

#381 ‒ Alzheimer’s disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

Part 1: Introduction, Personal Context

Introduction to Women's Brain Health and Alzheimer's with Lisa Mosconi

Lisa Mosconi's Personal Journey into Alzheimer's Research and Early Awareness

Part 2: Defining Alzheimer's and the Gender Gap

Preclinical Alzheimer's, Discomfort, and Distinguishing Different Forms of Dementia

Alzheimer's Disproportionately Affects Women: Challenging the Longevity Explanation

Incidence vs. Prevalence and Midlife Brain Changes in Women

Part 3: Brain Imaging and Estrogen Receptors

Menopause, Brain Imaging, and Alzheimer's Risk Factors in Women

Brain Estrogen Imaging and Estrogen Receptor Density in Women

Hormone Therapy, Estrogen Receptors, and mRNA Expression

Estrogen's Impact on Neuronal Tissues and Brain Compensation

Part 4: The CARE Initiative and Genetic Risk

Brain's Demand for Estrogen and the CARE Initiative

CARE Initiative Goals, Sex-Aggregated Risk Factors, and APOE4

Part 5: Hormone Therapy and Clinical Research

Hormone Replacement Therapy and Alzheimer's Risk: The Women's Health Initiative

CARE Initiative's Approach to Hormone Therapy and Alzheimer's Risk

Selective Estrogen Receptor Modulators (SERMs) and Brain Function

Estrogen and Breast Cancer: Addressing Misconceptions and the Women's Health Initiative

Part 6: Biomarkers and Future Outlook

Biomarkers, Prospective Trials, and the Lancet Commission

Oophorectomy, Hormone Therapy, and GLP-1 Agonists

Lifestyle Levers, Optimism for Dementia Treatments, and Disclosures

#381 ‒ Alzheimer’s disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

Part 1: Introduction, Personal Context

00:09Introduction to Women's Brain Health and Alzheimer's with Lisa Mosconi

Introduction to Women's Brain Health and Alzheimer's with Lisa Mosconi

03:13Lisa Mosconi's Personal Journey into Alzheimer's Research and Early Awareness

Lisa Mosconi's Personal Journey into Alzheimer's Research and Early Awareness

Part 2: Defining Alzheimer's and the Gender Gap

07:09Preclinical Alzheimer's, Discomfort, and Distinguishing Different Forms of Dementia

Preclinical Alzheimer's, Discomfort, and Distinguishing Different Forms of Dementia

10:42Alzheimer's Disproportionately Affects Women: Challenging the Longevity Explanation

Alzheimer's Disproportionately Affects Women: Challenging the Longevity Explanation

18:36Incidence vs. Prevalence and Midlife Brain Changes in Women

Incidence vs. Prevalence and Midlife Brain Changes in Women

Part 3: Brain Imaging and Estrogen Receptors

24:50Menopause, Brain Imaging, and Alzheimer's Risk Factors in Women

Menopause, Brain Imaging, and Alzheimer's Risk Factors in Women

35:10Brain Estrogen Imaging and Estrogen Receptor Density in Women

Brain Estrogen Imaging and Estrogen Receptor Density in Women

45:15Hormone Therapy, Estrogen Receptors, and mRNA Expression

Hormone Therapy, Estrogen Receptors, and mRNA Expression

53:01Estrogen's Impact on Neuronal Tissues and Brain Compensation

Estrogen's Impact on Neuronal Tissues and Brain Compensation

Part 4: The CARE Initiative and Genetic Risk

1:00:32Brain's Demand for Estrogen and the CARE Initiative

Brain's Demand for Estrogen and the CARE Initiative

1:07:26CARE Initiative Goals, Sex-Aggregated Risk Factors, and APOE4

CARE Initiative Goals, Sex-Aggregated Risk Factors, and APOE4

Part 5: Hormone Therapy and Clinical Research

1:11:33Hormone Replacement Therapy and Alzheimer's Risk: The Women's Health Initiative

Hormone Replacement Therapy and Alzheimer's Risk: The Women's Health Initiative

1:17:21CARE Initiative's Approach to Hormone Therapy and Alzheimer's Risk

CARE Initiative's Approach to Hormone Therapy and Alzheimer's Risk

1:23:54Selective Estrogen Receptor Modulators (SERMs) and Brain Function

Selective Estrogen Receptor Modulators (SERMs) and Brain Function

1:29:45Estrogen and Breast Cancer: Addressing Misconceptions and the Women's Health Initiative

Estrogen and Breast Cancer: Addressing Misconceptions and the Women's Health Initiative

Part 6: Biomarkers and Future Outlook

1:37:40Biomarkers, Prospective Trials, and the Lancet Commission

Biomarkers, Prospective Trials, and the Lancet Commission

1:45:02Oophorectomy, Hormone Therapy, and GLP-1 Agonists

Oophorectomy, Hormone Therapy, and GLP-1 Agonists

1:53:03Lifestyle Levers, Optimism for Dementia Treatments, and Disclosures

Lifestyle Levers, Optimism for Dementia Treatments, and Disclosures